Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma
Launched by UNIVERSITY HOSPITAL, LILLE · Sep 29, 2022
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new approach for treating advanced basal cell carcinoma (BCC), which is a type of skin cancer that can be difficult to manage, especially when it's located in sensitive areas of the body. The study aims to see if combining a treatment called Sonic Hedgehog inhibitors (specifically Vismodegib and Sonidegib) with radiotherapy can help prevent the cancer from coming back after patients have initially responded well to the medication. Researchers believe that this combination might lead to better outcomes for patients who have already achieved a complete response to the inhibitors.
To participate in this trial, individuals must be over 18 years old and have locally advanced BCC that has completely responded to the Sonic Hedgehog inhibitors, confirmed by a tissue sample. People with certain conditions, such as distant spread of cancer or prior radiation to the treatment area, will not be eligible. The trial is not yet recruiting participants, but once it begins, those who join can expect thorough monitoring and support throughout the process as researchers evaluate the effectiveness of this new treatment strategy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient over 18 years
- • Locally advanced non-recurrent BCC in complete response after first course of SHHi
- • Complete response has to be confirmed histologically
- • Available photography or CT scan before SHHi treatment allowing delineation of the initial tumor
- Exclusion Criteria:
- • Patients with distant metastasis
- • Patients with Gorlin's syndrome
- • Prior radiotherapy to the region of the studied cancer that would result in overlap of radiation therapy fields
- • Pregnant women
- • Life expectancy less than 1 year
- • Inability to receive informed consent
- • Inability to participate in the entire study
- • Lack of social security coverage
- • Refusal to sign consent
About University Hospital, Lille
University Hospital Lille is a leading academic medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the hospital leverages its extensive resources, multidisciplinary expertise, and state-of-the-art facilities to facilitate groundbreaking studies across various medical fields. Committed to enhancing therapeutic options and improving patient outcomes, University Hospital Lille collaborates with researchers, healthcare professionals, and industry partners to ensure rigorous scientific standards and ethical practices in all clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Laurent Mortier, MD,PhD
Principal Investigator
University Hospital, Lille
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials